CSL Of Australia Begins First Clinical Trials For H1N1 Flu Vaccine
This article was originally published in PharmAsia News
Executive Summary
Australia's CSL said human clinical trials have begun for its H1N1 flu virus, the first test to last seven weeks. The first batches are earmarked for Australia, Singapore and the United States, all of which have placed orders. French drug maker Sanofi-Aventis, as well as the World Health Organization, are expected to keep a close eye on the CSL trials for indications of how other H1N1 vaccine candidates might perform. An analyst noted there is little commercial advantage for a company to be the first in clinical trials for this vaccine, since so many governments have orders with several companies. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.